Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.65 |
| ▸ | FNTA | P49354 | 1/20 | 0.55 |
| ▸ | FNTB | P49356 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8694125 | 0.88 | MEN1 (0.67) | NPSR1MEN1KMT2AOPRD1OPRM1 | |
| SCHEMBL7101320 | 0.86 | MEN1 (0.51) | CYP2D6CYP19A1FNTAFNTBMEN1 | |
| SCHEMBL8304948 | 0.85 | MEN1 (0.55) | CYP2D6CYP19A1KDM4EMEN1KMT2A | |
| SCHEMBL9253495 | 0.83 | OPRD1 (0.49) | CYP2D6CYP19A1NPSR1MEN1KMT2A | |
| Norchlorcyclizine SCHEMBL7139140 | 0.81 | CYP2D6 (0.81) | CYP2D6CYP19A1KDM4ENPSR1MEN1 | |
| Norchlorcyclizine SCHEMBL6556514 | 0.81 | CYP2D6 (0.86) | CYP2D6CYP19A1KDM4EMEN1KMT2A | |
| Norchlorcyclizine SCHEMBL588655 | 0.81 | CYP2D6 (0.86) | CYP2D6CYP19A1KDM4EMEN1KMT2A | |
| Norchlorcyclizine SCHEMBL467086 | 0.81 | CYP2D6 (0.86) | CYP2D6CYP19A1KDM4EMEN1KMT2A | |
| SCHEMBL1137956 | 0.80 | CYP2D6 (1.00) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL14033470 | 0.80 | FNTA (0.43) | CYP2D6CYP19A1FNTAFNTBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1318996-B1 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORP (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6762186-B2 | USE TO TREAT ALLERGY, NASAL CONGESTION, INFLAMMATORY AND CENTRAL NERVOUS SYSTEM-RELATED DISEASES | SCHERING CORPORATION | 2004-07-13 | — | — | US | disclosed |
| CN-1461304-A | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | SCHERING CORP (US) | 2003-12-10 | — | — | CN | disclosed |
| EP-1020443-B1 | PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF | AZWELL INC (JP) | 2003-09-10 | — | — | EP | disclosed |
| EP-1318996-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | Schering Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020082278-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | SCHERING CORPORATION | 2002-06-27 | — | — | US | disclosed |
| WO-2002044141-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-06-06 | — | — | WO | disclosed |
| US-6172228-B1 | Process for producing piperazinesulfonamide derivatives and salts thereof | AZWELL INC. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-1020443-A1 | PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF | Azwell Inc. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082278-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | HRH3, HRH4, HRH2 | CYP2D6 1821/4885CYP19A1 2969/4885FNTA 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.